Human cytomegalovirus comprising exogenous antigens
US10995121B2 · kind B2 · utility
1Cited by
21References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 20, 2019 |
| Grant date | May 4, 2021 |
| Priority date | — |
| Expiry date | Aug 20, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.